References
- Bothwell LE, Greene JA, Podolsky SH, et al. Assessing the gold standard-lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175–2181. DOI:https://doi.org/10.1056/NEJMms1604593
- Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. DOI:https://doi.org/10.1056/NEJMoa063070
- Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. DOI:https://doi.org/10.1056/NEJMoa1303342
- Vestbo J, Anderson JA, Brook RD, SUMMIT Investigators, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. DOI:https://doi.org/10.1016/S0140-6736(16)30069-1
- Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. DOI:https://doi.org/10.1016/S0140-6736(16)31354-X
- Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. DOI:https://doi.org/10.1164/rccm.201703-0449OC
- Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. DOI:https://doi.org/10.1016/S0140-6736(18)30206-X
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. DOI:https://doi.org/10.1056/NEJMoa1713901
- Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. DOI:https://doi.org/10.1016/S2213-2600(18)30327-8
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35–48. DOI:https://doi.org/10.1056/NEJMoa1916046
- Rodriguez-Roisin R, Rabe KF, Vestbo J, all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/), et al. Global initiative for chronic obstructive lung disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J. 2017;50(1):1700671. DOI:https://doi.org/10.1183/13993003.00671-2017
- Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. DOI:https://doi.org/10.1164/rccm.201911-2207OC
- Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, Parallel-Group study. Am J Respir Crit Care Med. 2021;203(5):553–564. DOI:https://doi.org/10.1164/rccm.202006-2618OC
- Vestbo J. Fixed triple therapy in chronic obstructive pulmonary disease and survival. Living better, longer, or both? Am J Respir Crit Care Med. 2020;201(12):1463–1464. DOI:https://doi.org/10.1164/rccm.202003-0622ED
- Calverley P. Reigniting the TORCH: Chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited. Am J Respir Crit Care Med. 2021;203(5):531–532. DOI:https://doi.org/10.1164/rccm.202012-4300ED
- FDA. Food and Drug Aministration. https://wwwfdagov/media/143921/download. 2020.
- Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021;9(7):684–685.
- Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724. DOI:https://doi.org/10.1056/NEJMe1716802
- Suissa S, Ariel A. Triple therapy in COPD: only for the right patient. Eur Respir Med. 2019;53(4):1900394. DOI:https://doi.org/10.1183/13993003.00394-2019
- Suissa S. Ten commandments for randomized trials of pharmacological therapy for COPD and other lung diseases. Copd. 2021; Sept 1: 1–8. DOI:https://doi.org/10.1080/15412555.2021.1968816
- Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir Med. 2018;52(6):1801848. DOI:https://doi.org/10.1183/13993003.01848-2018
- Miettinen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol. 1989;42(4):325–331. DOI:https://doi.org/10.1016/0895-4356(89)90037-1
- Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13–15. DOI:https://doi.org/10.1097/EDE.0b013e3181c1ea43
- Renoux C, Dell’Aniello S, Brenner B, et al. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2017;26(5):554–560. DOI:https://doi.org/10.1002/pds.4197
- Thorlund K, Haggstrom J, Park JJ, et al. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698. DOI:https://doi.org/10.1136/bmj.k698
- Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med. 2016;26:16068.
- Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European respiratory society guideline. Eur Respir J. 2020;55:2000351. DOI:https://doi.org/10.1183/13993003.00351-2020
- Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. DOI:https://doi.org/10.1136/thx.2004.034280
- Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. DOI:https://doi.org/10.1056/NEJMoa1407154
- Rossi A, van der Molen T, del OR, et al. Instead: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. DOI:https://doi.org/10.1183/09031936.00126814
- Chapman KR, Hurst JR, Frent S-M, et al. Long-Term triple therapy De-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. DOI:https://doi.org/10.1164/rccm.201803-0405OC